Coronavirus disease-2019 (COVID-19), a viral respiratory illness caused by the severe acute
respiratory syndrome-coronavirus-2 (SARS-CoV-2), may predispose patients to thrombotic …

Background We evaluated whether rivaroxaban alone or in combination with aspirin would
be more effective than aspirin alone for secondary cardiovascular prevention. Methods In this …

Background Dabigatran is an oral direct thrombin inhibitor that has been shown to be an
effective alternative to warfarin in patients with atrial fibrillation. We evaluated the use of …

Background— The use of multiple antithrombotic drugs and aggressive invasive strategies
has increased the risk of major bleeding in acute coronary syndrome (ACS) patients. It is not …

Background— We studied whether aspirin resistance, defined as failure of suppression of
thromboxane generation, increases the risk of cardiovascular events in a high-risk population. …

For more than 20 years, moderately raised concentrations of total homocysteine (tHcy) have
been associated with an increased risk of atherothrombotic vascular events but only …

Background— Dabigatran 150 and 110 mg twice a day and warfarin are effective for stroke
prevention in atrial fibrillation. The purpose of this study was to compare their risks of …

Background Evidence from a recent trial has shown that the antiinflammatory effects of
colchicine reduce the risk of cardiovascular events in patients with recent myocardial infarction, …

Purpose: To review epidemiologic studies on the association between homocyst(e)ine level
and risk for cardiovascular disease and the potential benefits of homocysteine-decreasing …

Background Idarucizumab, a monoclonal antibody fragment, was developed to reverse the
anticoagulant effect of dabigatran. Methods We performed a multicenter, prospective, open-…